In order to produce small-molecule treatments that target proteins that are considered “undruggable,” Think Bioscience, a synthetic biology firm located in Boulder, Colorado, obtained $6 million in seed investment.
Investors
- YK Bioventures
- Existing investors
- the total capital amount rose to $26 million
The company’s pipeline will speed up with the extra funding.
Dr. Wendy Young will be joining Nick Saccomano, a seasoned drug developer, on the board of directors. For more than thirty years, Dr. Young has occupied prominent roles in the biopharmaceutical industry.
Most recently, she worked for fifteen years as a Senior Vice President of Small Molecule Drug Discovery and co-led research at Genentech. She is an adviser at Google Ventures and presently serves on the SABs of Think and a number of other biotech firms.
About Think Bioscience
Think Bioscience is redefining synthetic biology by employing living systems to direct the creation and assembly of pharmaceuticals, under the direction of co-founder and CEO Dr. Jerome Fox. The business genetically modifies bacteria to produce tiny compounds that attach to useful pockets; they then utilize these pockets to search for hits in the drug-like domain. GTPases, proteases, kinases, and protein tyrosine phosphatases (PTPs) are now included in the platform technology.
